Enviar pesquisa
Carregar
Testing for BPA and other EDCs
•
0 gostou
•
675 visualizações
NMS Labs
Seguir
Testing for Bisphenol A and other Endocrine Disruptor Chemicals Lee Blum, Ph.D.
Leia menos
Leia mais
Saúde e medicina
Denunciar
Compartilhar
Denunciar
Compartilhar
1 de 34
Baixar agora
Baixar para ler offline
Recomendados
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]
Eugene Elwell
Quantitative analysis of bpa and bpf - Christina Drescher
Quantitative analysis of bpa and bpf - Christina Drescher
tru-ugc
Method Validation: Comparison among two analitical methods for the determinat...
Method Validation: Comparison among two analitical methods for the determinat...
Greta SuperTramp
Overview 2014
Overview 2014
eman youssif
Salud vital mayo_05
Salud vital mayo_05
pedromacula
Occupy Chaplaincy
Occupy Chaplaincy
stefwarren
Gmail1
Gmail1
sup21077
Developments in Toxicology Support for the DRE Community
Developments in Toxicology Support for the DRE Community
NMS Labs
Mais conteúdo relacionado
Semelhante a Testing for BPA and other EDCs
Ccp(2) phong qiushi -ori
Ccp(2) phong qiushi -ori
Phong Shi
Application of Physiologically-based Kinetic Models in Exposure Modeling
Application of Physiologically-based Kinetic Models in Exposure Modeling
IES / IAQM
News on intra-abdominal hypertension - focus on fluids and hemodyknamics
News on intra-abdominal hypertension - focus on fluids and hemodyknamics
International Fluid Academy
Laboratory reference range values app17
Laboratory reference range values app17
Elsa von Licy
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]
ORALFLUIDLEADTEST
EPA trials for primary prevention of bowel cancer & metastatic disease, with ...
EPA trials for primary prevention of bowel cancer & metastatic disease, with ...
Igennus Healthcare Nutrition
Symposium presentation: Development of a Dried Blood Spot Method for Leptin
Symposium presentation: Development of a Dried Blood Spot Method for Leptin
JACK MAGGIORE
AAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_Russell
Lawrence Hwang
Use of iohexol clearance in dogs as a diagnostic test
Use of iohexol clearance in dogs as a diagnostic test
Dr.hema hassan
Thesis presentation
Thesis presentation
Valeria Girlus
Oligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake Laboratories
Pine Lake Laboratories
Materials And Methods Of Chemicals
Materials And Methods Of Chemicals
Angela Williams
Drugs of Abuse in Post Mortem Blood Poster
Drugs of Abuse in Post Mortem Blood Poster
Rick Youngblood
M.Sc. VIVA UPM - NURHAFZAN ANIS ISMAIL
M.Sc. VIVA UPM - NURHAFZAN ANIS ISMAIL
Saiful Irwan Zubairi
The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...
The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...
PerkinElmer, Inc.
Research presentation for the first international nursing research conferenc...
Research presentation for the first international nursing research conferenc...
Monina Gesmundo
Vasopressin Case Study
Vasopressin Case Study
Jennifer Wood
buchanania lanzan hepatocarcinoma presentation
buchanania lanzan hepatocarcinoma presentation
Srota Dawn
Humanbecoming
Humanbecoming
Mariah Lofgran
Rapid, cost effective and disposable device for saliva collection and process...
Rapid, cost effective and disposable device for saliva collection and process...
Robert Gellibolian, Ph.D
Semelhante a Testing for BPA and other EDCs
(20)
Ccp(2) phong qiushi -ori
Ccp(2) phong qiushi -ori
Application of Physiologically-based Kinetic Models in Exposure Modeling
Application of Physiologically-based Kinetic Models in Exposure Modeling
News on intra-abdominal hypertension - focus on fluids and hemodyknamics
News on intra-abdominal hypertension - focus on fluids and hemodyknamics
Laboratory reference range values app17
Laboratory reference range values app17
Gardner, lynn (atlanta_3)[1][1]
Gardner, lynn (atlanta_3)[1][1]
EPA trials for primary prevention of bowel cancer & metastatic disease, with ...
EPA trials for primary prevention of bowel cancer & metastatic disease, with ...
Symposium presentation: Development of a Dried Blood Spot Method for Leptin
Symposium presentation: Development of a Dried Blood Spot Method for Leptin
AAPS 2015_W3081_Biomarker Screening Poster_Russell
AAPS 2015_W3081_Biomarker Screening Poster_Russell
Use of iohexol clearance in dogs as a diagnostic test
Use of iohexol clearance in dogs as a diagnostic test
Thesis presentation
Thesis presentation
Oligonucleotide Capabilities at Pine Lake Laboratories
Oligonucleotide Capabilities at Pine Lake Laboratories
Materials And Methods Of Chemicals
Materials And Methods Of Chemicals
Drugs of Abuse in Post Mortem Blood Poster
Drugs of Abuse in Post Mortem Blood Poster
M.Sc. VIVA UPM - NURHAFZAN ANIS ISMAIL
M.Sc. VIVA UPM - NURHAFZAN ANIS ISMAIL
The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...
The Analysis of Baby Foods and Juices for Metals to Protect a Sensitive Popul...
Research presentation for the first international nursing research conferenc...
Research presentation for the first international nursing research conferenc...
Vasopressin Case Study
Vasopressin Case Study
buchanania lanzan hepatocarcinoma presentation
buchanania lanzan hepatocarcinoma presentation
Humanbecoming
Humanbecoming
Rapid, cost effective and disposable device for saliva collection and process...
Rapid, cost effective and disposable device for saliva collection and process...
Mais de NMS Labs
Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
NMS Labs
The Challenges of Analytical Method Validation for Hallucinogens and Designer...
The Challenges of Analytical Method Validation for Hallucinogens and Designer...
NMS Labs
Trends Report on Changes in the Designer Drug Market: Spring 2012
Trends Report on Changes in the Designer Drug Market: Spring 2012
NMS Labs
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
NMS Labs
Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
NMS Labs
Designer Drugs Testing Solutions for Employers
Designer Drugs Testing Solutions for Employers
NMS Labs
Oral Fluid as a Chemical Test for the DRE Program
Oral Fluid as a Chemical Test for the DRE Program
NMS Labs
K2 and Beyond: A Synthetic Cannabinoid Primer
K2 and Beyond: A Synthetic Cannabinoid Primer
NMS Labs
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
NMS Labs
Salvia: Effects, Legal Status and Analysis
Salvia: Effects, Legal Status and Analysis
NMS Labs
New Highs: Salvia and K 2 - Solutions for the DRE
New Highs: Salvia and K 2 - Solutions for the DRE
NMS Labs
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
NMS Labs
NMS Labs introduction
NMS Labs introduction
NMS Labs
Mais de NMS Labs
(13)
Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
Increasing Diversity of Chemicals in Synthetic Stimulant and Cathinone Cases
The Challenges of Analytical Method Validation for Hallucinogens and Designer...
The Challenges of Analytical Method Validation for Hallucinogens and Designer...
Trends Report on Changes in the Designer Drug Market: Spring 2012
Trends Report on Changes in the Designer Drug Market: Spring 2012
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
The Expanding Reach of the Designer Drug Movement in 2011: Challenges for For...
Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
Pharmacodynamics and Pharmacokinetics of Synthetic Cannabinoids
Designer Drugs Testing Solutions for Employers
Designer Drugs Testing Solutions for Employers
Oral Fluid as a Chemical Test for the DRE Program
Oral Fluid as a Chemical Test for the DRE Program
K2 and Beyond: A Synthetic Cannabinoid Primer
K2 and Beyond: A Synthetic Cannabinoid Primer
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
K2 and the Synthetic Cannabinoids: Pharmacology, Effects and Chemical Analysis
Salvia: Effects, Legal Status and Analysis
Salvia: Effects, Legal Status and Analysis
New Highs: Salvia and K 2 - Solutions for the DRE
New Highs: Salvia and K 2 - Solutions for the DRE
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
NMS Labs Dinner Presentation by Dr. Andrea Gore 5-27-10
NMS Labs introduction
NMS Labs introduction
Último
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Naveenkumar267201
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
whalesdesign
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
HongBiThi1
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
Sujoy Dasgupta
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
Internal medicine department, faculty of Medicine Beni-Suef University Egypt
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
kishan singh tomar
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
kishan singh tomar
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
katiequigley33
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
Peter Embi
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
MedicoseAcademics
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Sujoy Dasgupta
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
Pradnya Wadekar
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
Medical University
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
HongBiThi1
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
HongBiThi1
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
Internal medicine department, faculty of Medicine Beni-Suef University Egypt
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
MAsifAhmad
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
DeepakDaniel9
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
Dolisha Warbi
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
Sujoy Dasgupta
Último
(20)
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
Testing for BPA and other EDCs
1.
Lee Blum, Ph.D.
Testing for Bisphenol A and other Endocrine Disruptor Chemicals
2.
3.
4.
Bisphenol A NTP
– The Study & The Results
5.
Bisphenol A –
It’s Everywhere
6.
7.
8.
9.
10.
BPA - Instrumentation
Hewlett Packard/Agilent 5973 MSD
11.
12.
BPA – Linearity
in Urine Observed Concentrations (ng/mL) Target Value Day 1 Day 2 Day 3 10.0 ng/mL 10.6 10.4 10.2 5.0 ng/mL 4.90 5.02 4.99 2.5 ng/mL 2.44 2.43 2.50 1.0 ng/mL 0.98 0.98 0.98 0.25 ng/mL 0.25 0.25 0.25
13.
BPA – Linearity
in Urine
14.
BPA - Within
Day Precision in Urine N = 5 x 3 Days 0.25 ng/mL 0.5 ng/mL 7.5 ng/mL Day 1 Mean 0.30 ± 0.015 0.44 ± 0.01 6.64 ± 0.1 %CV 5.83% 1.26% 0.82% % Accuracy 104% 87.2% 88.5% Day 2 Mean 0.25 ± 0.026 0.41 ± 0.008 6.77 ± 0.1 %CV 10.4% 1.99% 1.69% % Accuracy 101% 82% 90.3% Day 3 Mean 0.23 ± 0.015 0.44 ± 0.02 6.38 ± 0.5 %CV 6.48% 3.59% 7.24% % Accuracy 93.6% 88.0% 85.1%
15.
BPA - Between
Day Precision in Urine N = 5 x 3 Days 0.25 ng/mL 0.5 ng/mL 7.5 ng/mL Mean 0.25 ± 0.02 0.43 ± 0.02 6.6 ± 0.30 %CV 8.91% 3.87% 4.63% % Accuracy 100% 86.0% 87.9%
16.
Urine Sample Endogenous
(ng/mL) Spiked (ng/mL) Target (ng/mL) Measured (ng/mL) Deviation from Target 1 0.15 1.0 1.15 1.12 -2.61% 2 1.75 2.5 4.25 4.05 -4.71% 3 2.61 5.0 7.61 6.87 -9.72% 4 0.41 10.0 10.4 9.26 -11.0% 5 3.89 15.0 18.9 19.0 0.53% 6 0.31 0.25 0.56 0.54 -3.57% 7 1.78 1.0 2.78 2.69 -3.24% 8 0.47 2.5 2.97 2.81 -5.39% 9 1.30 5.0 6.30 6.07 -3.65% 10 0.16 1.0 1.16 1.04 -10.3% 11 0.24 2.5 2.74 2.62 -4.38% 12 4.82 5.0 9.82 9.06 -7.74% 13 0.90 0.25 1.15 1.08 -6.09% 14 0.57 1.0 1.57 1.50 -4.46% 15 0.57 2.5 3.07 2.92 -4.89% 16 1.78 5.0 6.78 6.63 -2.21% 17 2.70 0.25 2.95 3.01 2.03% 18 4.28 1.0 5.28 5.26 -0.38% 19 1.08 2.5 3.58 3.06 -14.5% Mean Endogenous 1.57 ± 1.46 ng/mL Mean Bias -5.07 ± 4.15%
17.
BPA – Storage
Stability in Urine
18.
BPA – Storage
Stability in Urine
19.
BPA – Storage
Stability in Urine
20.
BPA – Patient
Urine Samples Samples Tested 36 Median 3.2 ng/mL Range <0.25 to >10 ng/mL
21.
BPA – 0.25
ng/mL in Urine
22.
BPA – Typical
Urine Sample
23.
24.
BPA – Linearity
in Serum
25.
BPA – Linearity
in Blood
26.
BPA - Within
Day Precision in Serum N = 5 0.25 ng/mL 0.75 ng/mL 7.5 ng/mL Mean 0.21 ± 0.01 0.80 ± 0.06 7.61 ± 0.26 %CV 5.12% 6.94% 3.42% % Accuracy 85.6% 106% 102%
27.
BPA – Spiked
Plasma Samples Plasma Sample Endogenous (ng/mL) Spiked (ng/mL) Target (ng/mL) Measured (ng/mL) Deviation from Target 1 0.22 0.25 0.47 0.47 0.00% 2 0.22 2.50 2.72 2.63 -3.31% 3 0.67 0.50 1.17 1.15 -1.71% 4 0.67 5.00 5.67 5.48 -3.35% 5 0.26 1.00 1.26 1.30 3.17% 6 0.26 10.0 10.3 10.0 -2.53% 7 0.11 0.75 0.86 0.92 6.98% 8 0.11 7.50 7.61 7.52 -1.18% 9 2.10 3.00 5.10 5.31 4.12% 10 2.10 9.00 11.1 11.3 1.62% Mean Endogenous 0.67 ± 0.83 ng/mL Mean Bias 0.38 ± 3.49 %
28.
BPA – Spiked
Blood Samples Blood Sample Endogenous (ng/mL) Spiked (ng/mL) Target (ng/mL) Measured (ng/mL) Deviation from Target NaF 0.08 0.25 0.33 0.36 9.09% NaF 0.08 2.50 2.58 2.86 10.8% K Oxalate 0.17 0.50 0.67 0.70 4.48% K Oxalate 0.17 5.00 5.17 6.06 17.2% Na EDTA 0.18 1.00 1.18 1.32 11.9% Na EDTA 0.18 10.0 10.2 12.2 19.4% K EDTA 0.12 0.75 0.87 0.83 -4.60% K EDTA 0.12 7.50 7.62 9.00 18.1% Na Heparin 0.22 3.00 3.22 3.30 2.48% Na Heparin 0.22 9.00 9.22 10.1 9.54% Mean Endogenous 0.15 ± 0.05 ng/mL Mean Bias 9.85 ± 7.54%
29.
BPA – Storage
Stability in Serum
30.
BPA – 0.25
ng/mL in Serum
31.
BPA – 0.75
ng/mL in Blood
32.
33.
34.
[email_address] Phone: 1-800-522-6671
Lee Blum, Ph.D.
Baixar agora